Navigation Links
Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine
Date:6/19/2013

emissions lasting in excess of two years in the great majority of patients treated."  

Study participants were enrolled selected to receive either ibrutinib 420 mg (n=51) or 840 mg (n=34) as a once-daily, oral monotherapy. Both doses were associated with overall response rates of 71 percent. Del17p patients had an overall response rate of 68 percent. Two patients in the 420 mg dose arm had complete responses and 34 patients had partial responses. Across all relapsed or refractory patients, including the high risk patients, the estimated progression-free survival at 26 months was 75 percent. An additional 20 percent of patients treated with the 420 mg dose and 15 percent of patients taking the 840 mg dose achieved a partial response accompanied by lymphocytosis, an elevated blood lymphocyte count.

The majority of adverse events (AEs) observed in the study were considered to be Grade 1 or 2 in severity, including diarrhea, infections and fatigue. A total of six patients taking ibrutinib experienced an AE leading them to discontinue treatment with the drug. Severe AEs observed during the treatment period include pneumonia and dehydration (12 percent and six percent, respectively), as well anemia, neutropenia and thrombocytopenia (six percent, 15 percent and six percent, respectively). Grade 3-4 hematological toxicities were not common.

Data from this study were presented at the annual meeting of the American Society of Hematology in December 2012.

Study Design
The Phase 1b/2, open-label, multicenter study was designed to determine the safety, efficacy, pharmacokinetics and pharmacodynamics of ibrutinib in patients with relapsed or refractory CLL. The primary objective of the study was to determine the safety of the two fixed-dose regimens of ibrutinib, assessed by evaluating the frequency and severity of AEs. Secondary efficacy endpoints included: overall response rate, progression-free survival and an exploratory endpoint of overa
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib (PCI-32765) at the 2012 Annual Meeting of the American Society of Clinical Oncology
2. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
3. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, Suggest High and Durable Responses in Relapsed/Refractory Mantle Cell Lymphoma
4. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, in Relapsed/Refractory Mantle Cell Lymphoma Presented at American Society of Hematology Annual Meeting
5. Ibrutinib Receives Two Oncology Breakthrough Therapy Designations from U.S. Food and Drug Administration
6. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
7. Phase II Ibrutinib Monotherapy Study Shows CLL Patients Achieved Rapid and Sustainable Disease Control Irrespective of Age or High Risk Prognostic Factor
8. Ibrutinib Expanded Access Program Open to Eligible U.S. Patients with Relapsed or Refractory Mantle Cell Lymphoma
9. Ibrutinib Phase 2 Data: Analyses Show Efficacy with Ibrutinib Monotherapy in Patients with Relapsed or Refractory Mantle Cell or Diffuse Large B-cell Lymphoma
10. Updated Results of Two Phase 2 Ibrutinib Studies in Patients with Mantle Cell Lymphoma or Diffuse Large B-cell Lymphoma
11. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... WILSONVILLE, Ore. , Aug. 29, 2014 /PRNewswire-iReach/ ... its Accessory (Axilla) Strap for the SAM Junctional ... SAM Medical Products announced ... a voluntary recall to address a potential issue ... strap used for the Axilla application of the ...
(Date:8/29/2014)... SAN DIEGO , Aug. 29, 2014 /PRNewswire/ ... an emerging biopharmaceutical company, announced today that Santosh ... will be leaving the Company, for personal reasons, ... the Chief Medical Officer of Aires Pharmaceuticals, which ... Vetticaden,s former responsibilities as the Company,s interim Chief ...
(Date:8/29/2014)... , Aug. 29, 2014  BC Technical, the ... acquired Polaris Medical Imaging, a leader in sales, service ... strategic acquisition allows BC Technical to continue to expand ... within MR and CT modalities. "We ... said Mark Alvarez , president and CEO of ...
Breaking Medicine Technology:SAM Medical Products Implements Voluntary Recall of its Accessory (Axilla) Strap for the SAM Junctional Tourniquet. 2Mast Therapeutics Announces Management Change 2Mast Therapeutics Announces Management Change 3Mast Therapeutics Announces Management Change 4BC Technical Acquires Polaris Medical Imaging 2
...  A global executives, organization, meeting in San Francisco to ... well as bankers and other investors, today called on ... an effort by others in business, education, government and ... solving the nation,s healthcare crisis. The proclamation ...
...   MX.com today introduced a new Pelvic Floor ... administrators add new hospital service lines to reach aging ... the program integrates treatment for complex pelvic health issues. ... 900 percent and demand continues to surge.    ...
Cached Medicine Technology:Leaders of Healthcare, Biotech and Pharmaceutical Companies Sending Proclamation to President Obama and Congress Urging Solution to Nation's Healthcare Crisis 2MX.com Launches Pelvic Health Program Model to Help Hospitals Rapidly Expand Key Services 2
(Date:8/30/2014)... CO (PRWEB) August 30, 2014 In today’s ... increasingly difficult to get. Snoring and sleep apnea (a medical ... rob people and their bed partners of the rest they ... 45% of the population snores and 20 million people in ... 10% have been diagnosed and treated; and of those treated, ...
(Date:8/30/2014)... "My niece developed a nighttime fever, and ... her fever might get worse," said an inventor from ... of how she was doing, I developed this monitoring ... monitor a child's temperature. The unit instantly alerts parents ... prompt medical care can be given, which is designed ...
(Date:8/30/2014)... August 2014: Transvenous lead extraction (TLE) is clinically successful ... from the European Lead Extraction ConTRolled (ELECTRa) registry presented ... by Dr Maria Grazia Bongiorni, chair of the registry,s ... cardiac implantable electronic devices (CIED) implant procedures has grown ... of complications has increased and leads are often the ...
(Date:8/30/2014)... 2014 The new review published by Daily ... by Karen Brimeyer, who wanted to make her guide accessible ... guide is now easy to find in the form of ... guide, the author of the new method shares all her ... Gossip writes in its review that the leaky gut syndrome ...
(Date:8/30/2014)... Flagstaff, AZ (PRWEB) August 30, 2014 Jake ... High School while in the Back2Basics Outdoor Adventures ... want to finish high school so I can actually start ... need English and math, and I'm done.” , He has ... the initial Back2Basics program. Most clients choose to continue on ...
Breaking Medicine News(10 mins):Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Transvenous lead extraction clinically successful in 98 percent of cases 2Health News:Transvenous lead extraction clinically successful in 98 percent of cases 3Health News:Leaky Gut Cure Review Reveals Unique Method to Stop Chronic Symptoms 2
... Programs to Help Payers and Providers Contain Costs and ... Improve Patient Outcomes ... announced the,launch of Innovent Oncology, a service division that offers ... through,integrated programs designed specifically for the complexity of cancer,care. With ...
... led by Professor Nicola T. Lautenschlager, the Chair of ... published in the international journal Journal of the ... The Fitness for the Ageing Brain Study, conducted over ... believed to be the first in the world to ...
... Health Risk, ROCHESTER, Minn., Sept. 2 ... of Mayo Clinic Women,s HealthSource.,You may cite ... Mayo Clinic Women,s,HealthSource attribution is required. Reprinting ... subscription information as your editorial policies,permit: Visit ...
... the Dallas,litigation firm Sayles Werbner are announcing a rare ... for the family of a man who,died of a ... his,admission to a hospital emergency room for chest pains., ... Friday in Columbia Medical,Center of Los Colinas Inc. d/b/a ...
... Gustav has weakened to a tropical depression, the American ... areas until authorities,deem it safe to return., "We ... they think the,danger has passed," said Joe Becker, Senior ... be patient, since conditions are,still unsafe in many places." ...
... YORK, Sept. 2 "Move over, Madonna," read a recent,San ... Chant -,Music for the Soul debuted at #9 on the ... and above Grammy Best New Artist of the,Year Amy Winehouse. ... Germany,Platinum in Belgium and Poland, and Double Platinum in Austria. ...
Cached Medicine News:Health News:US Oncology Launches New Services Division: Innovent Oncology 2Health News:US Oncology Launches New Services Division: Innovent Oncology 3Health News:US Oncology Launches New Services Division: Innovent Oncology 4Health News:Australian over-50s walk away memory problems in world-first trial 2Health News:September 2008 Mayo Clinic Women's HealthSource Highlights Normal Weight Obesity, Regular Exercise and Cholesterol 2Health News:September 2008 Mayo Clinic Women's HealthSource Highlights Normal Weight Obesity, Regular Exercise and Cholesterol 3Health News:September 2008 Mayo Clinic Women's HealthSource Highlights Normal Weight Obesity, Regular Exercise and Cholesterol 4Health News:Sayles Werbner Earns Rare Texas Supreme Court Ruling Upholding Punitive Damages Award in Medical Malpractice Case 2Health News:Red Cross Advises Evacuees to Stay Put Until Conditions Are Safe 2
Clearview H. pylori II uses rapid, two-step technology for the direct detection of H. pylori antibodies. , ,The patented, innovative technology used by Clearview H. pylori II provides highly sen...
... HP is a visually read, qualitative immunochromatographic ... H. pylori, a bacterium that grows in ... ulcer disease and some gastric cancers. FlexSure ... blood or serum samples, provides the physician ...
... 5 minutes immunoassay, based on a ... monoclonal antibody, for the qualitative detection ... stool. The Premier Platinum HpSA, a ... extensive evaluation, was accepted as an ...
... is designed to detect the IgM ... whole blood. The QuickVue+ Infectious Mononucleosis ... erythrocytes which give a greater sensitivity ... from sheep and horse erythrocytes. QuickVue+ ...
Medicine Products: